BioNTech SE (22UAy)

156.70
+4.70(+3.09%)
  • Volume:
    1,460
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    151.85 - 157.70

22UAy Overview

Prev. Close
152
Day's Range
151.85-157.7
Revenue
18.56B
Open
152.7
52 wk Range
110.14-262.92
EPS
42.44
Volume
1,460
Market Cap
37.6B
Dividend (Yield)
1.5498
(0.94%)
Average Vol. (3m)
2,652
P/E Ratio
3.98
Beta
0.162
1-Year Change
-40.76%
Shares Outstanding
243,019,216
Next Earnings Date
Mar 29, 2023
What is your sentiment on BioNTech?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE News

BioNTech SE Analysis

BioNTech SE Company Profile

BioNTech SE Company Profile

Employees
4000
  • Type:Equity
  • Market:Germany
  • ISIN:US09075V1026
  • WKN:A2PSR2

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Read More

Analyst Price Target

Average203.46 (+25.11% Upside)
High309.57
Low142.82
Price162.63
No. of Analysts16
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyBuyBuyBuy
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Buy
  • who want buy this can you tell me. So many court is coming. They will must pay a lot for deaths. Full twitter so whole world know
    0
    • The mRNA vaccine looks like a joke in the vaccine history. It couldn't stop COVID infection and spreading. Biden, Fauci, the head of CDC and The CEO of Pfizer were infected COVID virus after they got 4 shots of mRNA vaccine. Does mRNA vaccine can generate enough folded spike protein as antigen for Antigen presenting cells? Who knows? mRNA vaccine looks like generating shot term nonspecific immune response by its longer RNA chain.
      8
      • You mean China is a big performer. Funny.
        0
    • i bought in yesterday and look tank city i am the kiss of death
      0
      • I got in and tank city I would sell o am the kiss of death it will never see green again unless I get out
        0
        • oh my Biden has just put a howitzer missle plus a drone strike into the vaccine stocks
          0
          • Anyone can recommend me some books to improve my operations? In particular on how to manage my capital. Thank you
            1
            • wow
              0
              • wow brutal glad I am out
                0
                • Powell has destroyed the market
                  0
                  • Biden just destroyed all the vaccine stocks liquidate now it will never see green again
                    1